Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Tuberculosis

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 161 articles:
HTML format
Text format



Single Articles


    November 2017
  1. DENTI P, Garcia-Prats AJ, Draper HR, Wiesner L, et al
    Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01521.
    PubMed     Text format     Abstract available


  2. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, et al
    Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.00420.
    PubMed     Text format     Abstract available


  3. HEYCKENDORF J, Andres S, Koser CU, Olaru ID, et al
    What is resistance? Impact of phenotypic versus molecular drug resistance testing on multi- and extensively drug-resistant tuberculosis therapy.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01550.
    PubMed     Text format     Abstract available


    October 2017
  4. SUN Q, Xiao TY, Liu HC, Zhao XQ, et al
    Mutations within embCAB are associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01279.
    PubMed     Text format     Abstract available


  5. WILLBY MJ, Wijkander M, Havumaki J, Johnson K, et al
    Detection of Mycobacterium tuberculosis pncA mutations by the NIPRO GenoscholarPZA-TB II as compared to conventional sequencing.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01871.
    PubMed     Text format     Abstract available


  6. BERUBE BJ, Parish T
    Combinations of respiratory chain inhibitors have enhanced bactericidal activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01677.
    PubMed     Text format     Abstract available


  7. GENESTET C, Ader F, Pichat C, Lina G, et al
    Combined Antibacterial Effect of Isoniazid and Rifampicin on Four Mycobacterium tuberculosis Strains: in Vitro Experiments and Response-Surface Modeling.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01413.
    PubMed     Text format     Abstract available


  8. XU J, Tasneen R, Peloquin CA, Almeida DV, et al
    Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01692.
    PubMed     Text format     Abstract available


  9. DE WELZEN L, Eldholm V, Maharaj K, Manson AL, et al
    Whole transcriptome and genomic analysis of extensively drug-resistant Mycobacterium tuberculosis clinical isolates identifies downregulation of ethA as a mechanism of ethionamide resistance.
    Antimicrob Agents Chemother. 2017 Oct 9. pii: AAC.01461.
    PubMed     Text format     Abstract available


  10. NAKATANI Y, Opel-Reading HK, Merker M, Machado D, et al
    Role of alanine racemase mutations in Mycobacterium tuberculosis D-cycloserine resistance.
    Antimicrob Agents Chemother. 2017 Oct 2. pii: AAC.01575.
    PubMed     Text format     Abstract available


    September 2017
  11. XU W, DeJesus MA, Rucker N, Engelhart CA, et al
    Chemical genomic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01334.
    PubMed     Text format     Abstract available


  12. KIDWAI S, Park CY, Mawatwal S, Tiwari P, et al
    The dual mechanism of action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00969.
    PubMed     Text format     Abstract available


  13. METCALFE JZ, Streicher E, Theron G, Colman RE, et al
    Mycobacterium tuberculosis subculture results in loss of potentially clinically relevant heteroresistance.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00888.
    PubMed     Text format     Abstract available


  14. HUSZAR S, Singh V, Polcicova A, Barath P, et al
    N-Acetylglucosamine-1-phosphate transferase, WecA, as a validated drug target in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01310.
    PubMed     Text format     Abstract available


  15. PARK SW, Tasneen R, Converse PJ, Nuermberger EL, et al
    Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01502.
    PubMed     Text format     Abstract available


  16. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
    Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


  17. ARORA K, Ochoa-Montano B, Tsang PS, Blundell TL, et al
    Correction for Arora et al., "Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


    July 2017
  18. MOOSA A, Lamprecht DA, Arora K, Barry CE 3rd, et al
    Susceptibility of Mycobacterium tuberculosis cytochrome bd oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c.
    Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01338.
    PubMed     Text format     Abstract available


  19. MCNEIL MB, Dennison D, Shelton C, Parish T, et al
    In vitro isolation and characterization of oxazolidinone resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01296.
    PubMed     Text format     Abstract available


  20. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
    Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.01066.
    PubMed     Text format     Abstract available


  21. MOURIK BC, de Knegt GJ, Verbon A, Mouton JW, et al
    Assessment of bactericidal drug activity and treatment outcome in a mouse tuberculosis model using a clinical Beijing strain.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00696.
    PubMed     Text format     Abstract available


  22. PANG Y, Zong Z, Huo F, Jing W, et al
    In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00900.
    PubMed     Text format     Abstract available


  23. YANG SS, Hu YB, Wang XD, Gao YR, et al
    Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 17. pii: AAC.00551.
    PubMed     Text format     Abstract available


  24. VAN RIJN SP, Srivastava S, Wessels MA, van Soolingen D, et al
    The sterilizing effect of ertapenem-clavulanate in a hollow fiber model of tuberculosis and implications on clinical dosing.
    Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.02039.
    PubMed     Text format     Abstract available


  25. PATEL N, O'Malley T, Zhang YK, Xia Y, et al
    A novel 6-benzyl ether benzoxaborole is active against Mycobacterium tuberculosis in vitro.
    Antimicrob Agents Chemother. 2017 Jul 3. pii: AAC.01205.
    PubMed     Text format     Abstract available


    June 2017
  26. BABLISHVILI N, Tukvadze N, Shashkina E, Mathema B, et al
    The impact of gyrB and eis mutations in improving second-line drug resistance detection among Mycobacterium tuberculosis isolates from Georgia.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.01921.
    PubMed     Text format     Abstract available


  27. LI SY, Tasneen R, Tyagi S, Soni H, et al
    Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin and pyrazinamide in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00913.
    PubMed     Text format     Abstract available


  28. RAHMAN A, Ferdous SS, Ahmed S, Rahman SMM, et al
    Pyrazinamide susceptibility and pncA mutation profile of Mycobacterium tuberculosis among multi-drug resistant tuberculosis patients in Bangladesh.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00511.
    PubMed     Text format     Abstract available


  29. CHIREHWA MT, McIlleron H, Rustomjee R, Mthiyane T, et al
    Pharmacokinetics of Pyrazinamide: optimising dosing regimens for drug-sensitive and -resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00490.
    PubMed     Text format     Abstract available


  30. RODRIGUES FELIX C, Gupta R, Geden S, Roberts J, et al
    Selective Killing Of Dormant Mycobacterium tuberculosis By Marine Natural Products.
    Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00743.
    PubMed     Text format     Abstract available


  31. ZHANG Y, Zhang J, Cui P, Zhang W, et al
    Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008 and Rv1667c involved in pyrazinamide resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00940.
    PubMed     Text format     Abstract available


  32. SRIVASTAVA S, Magombedze G, Koeuth T, Sherman C, et al
    Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00751.
    PubMed     Text format     Abstract available


  33. FOFANA MO, Dowdy DW
    Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


  34. ANTHONY RM, Cynamon M, Hoffner S, Werngren J, et al
    Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


    May 2017
  35. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
    Pharmacokinetic evidence to support increased doses of rifampin for tuberculosis: results from the HIRIF trial.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00038.
    PubMed     Text format     Abstract available


  36. VAN'T BOVENEIND-VRUBLEUSKAYA N, Seuruk T, van Hateren K, van der Laan T, et al
    Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis patients.
    Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00343.
    PubMed     Text format     Abstract available


  37. SLOAN DJ, McCallum AD, Schipani A, Egan D, et al
    Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 May 1. pii: AAC.00210.
    PubMed     Text format     Abstract available


    April 2017
  38. NJIRE M, Wang N, Wang B, Tan Y, et al
    Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00070.
    PubMed     Text format     Abstract available


  39. VISWANATHAN G, Yadav S, Raghunand TR
    Identification of mycobacterial genes involved in antibiotic sensitivity - Implications in the treatment of tuberculosis with beta-lactam containing regimens.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00425.
    PubMed     Text format     Abstract available


  40. OLLIARO PL, Merle C, Mthiyane T, Bah B, et al
    Analysis of the effects on the QT interval of a gatifloxacin-containing regimen versus standard treatment of pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.01834.
    PubMed     Text format     Abstract available


  41. DANELISHVILI L, Shulzhenko N, Chinison JJJ, Babrak L, et al
    Mycobacterium tuberculosis proteome response to anti-tuberculosis compounds reveals metabolic "escape" pathways that prolong bacterial survival.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00430.
    PubMed     Text format     Abstract available


  42. JANG J, Kim R, Woo M, Jeong J, et al
    Efflux attenuates the anti-bacterial activity of Q203 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02637.
    PubMed     Text format     Abstract available


  43. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.00226.
    PubMed     Text format     Abstract available


  44. CHEN X, Hashizume H, Tomishige T, Nakamura I, et al
    Delamanid Kills Dormant Mycobacteria in Vitro and in the Guinea Pig Model of Tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.02402.
    PubMed     Text format     Abstract available


  45. VAN RIJN SP, Zuur MA, van Altena R, Akkerman OW, et al
    Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available


    March 2017
  46. XU J, Wang B, Hu M, Huo F, et al
    Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00239.
    PubMed     Text format     Abstract available


  47. ALSULTAN A, Savic R, Dooley KE, Weiner M, et al
    Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02625.
    PubMed     Text format     Abstract available


  48. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
    Erratum for Velasquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


    February 2017
  49. RAMACHANDRAN G, Kumar AK, Chandrasekaran V, Kannan T, et al
    Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in India.
    Antimicrob Agents Chemother. 2017 Feb 27. pii: AAC.02464.
    PubMed     Text format     Abstract available


  50. KAYIGIRE XA, Friedrich SO, van der Merwe L, Diacon AH, et al
    Acquisition of rifampin resistance in pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02220.
    PubMed     Text format     Abstract available


  51. CHOI SR, Britigan BE, Narayanasamy P
    Ga(III) Nanoparticles Inhibit Growth of Both TB and HIV and Release of IL-6 and IL-8 in Co-Infected Macrophages.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02505.
    PubMed     Text format     Abstract available


    January 2017
  52. AJILEYE A, Alvarez N, Merker M, Walker TM, et al
    Some synonymous and non-synonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-resistance results to fluoroquinolones with the Hain GenoType MTBDRsl assays.
    Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02169.
    PubMed     Text format     Abstract available


  53. DE JAGER V, van der Merwe L, Venter A, Donald PR, et al
    Time trends in sputum mycobacterial load and 2-day bactericidal activity of INH-containing anti-tuberculosis therapies.
    Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02088.
    PubMed     Text format     Abstract available


  54. KUMAR P, Kaushik A, Bell D, Chauhan V, et al
    Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.02234.
    PubMed     Text format     Abstract available


  55. VAN ALTENA R, Dijkstra JA, van der Meer ME, Borjas Howard JF, et al
    Reduced chance of hearing loss associated with Therapeutic Drug Monitoring of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.01400.
    PubMed     Text format     Abstract available


  56. SCHUMP MD, Fox DM, Bertozzi CR, Riley LW, et al
    Subcellular Partitioning and Intra-Macrophage Selectivity of Antimicrobial Compounds Against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jan 4. pii: AAC.01639.
    PubMed     Text format     Abstract available


    December 2016
  57. IACOBINO A, Piccaro G, Giannoni F, Mustazzolu A, et al
    Mycobacterium tuberculosis is selectively killed by rifampin and rifapentine in hypoxia at neutral pH.
    Antimicrob Agents Chemother. 2016 Dec 19. pii: AAC.02296.
    PubMed     Text format     Abstract available


  58. FOFANA MO, Shrestha S, Knight GM, Cohen T, et al
    Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model.
    Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.00498.
    PubMed     Text format     Abstract available


  59. PANG Y, Zhang Z, Wang Y, Wang S, et al
    Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000-2010: findings from the national survey data.
    Antimicrob Agents Chemother. 2016 Dec 5. pii: AAC.02170.
    PubMed     Text format     Abstract available


    November 2016
  60. BROSSIER F, Pham A, Bernard C, Aubry A, et al
    Molecular investigation of resistance to second line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01299.
    PubMed     Text format     Abstract available


  61. SEBASTIAN J, Swaminath S, Nair RR, Jakkala K, et al
    De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells formed against Antituberculosis Drugs In Vitro.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01343.
    PubMed     Text format     Abstract available


  62. YEE M, Gopal P, Dick T
    Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with pyrazinamide resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.02342.
    PubMed     Text format     Abstract available


  63. ROSEN BC, Dillon NA, Peterson ND, Minato Y, et al
    Long-Chain Fatty Acyl-CoA Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.02130.
    PubMed     Text format     Abstract available


  64. ANTWI S, Yang H, Enimil A, Sarfo AM, et al
    Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01701.
    PubMed     Text format     Abstract available


  65. ALFFENAAR JC, Akkerman OW, van Hest R
    Statin Adjunctive Therapy for Tuberculosis Treatment.
    Antimicrob Agents Chemother. 2016;60:7004.
    PubMed     Text format    


    October 2016
  66. PHOLWAT S, Stroup S, Heysell S, Ogarkov O, et al
    Eis C-14G and C-15G mutations do not confer kanamycin resistance in M. tuberculosis.
    Antimicrob Agents Chemother. 2016 Oct 10. pii: AAC.01775.
    PubMed     Text format     Abstract available


    September 2016
  67. WANG X, Yang S, Gu J, Deng J, et al
    Mycobacterium tuberculosis arylamine N-acetyltransferase acetylates and thus inactivates para-aminosalicylic acid.
    Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.01312.
    PubMed     Text format     Abstract available


  68. LI Y, Wang Y, Zhang Z, Gao H, et al
    Association between embB Codon 306 Mutations, Phenotypic Resistance Profiles and Genotypic Characterization in Clinical Mycobacterium tuberculosis Isolates from Hebei, China.
    Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.00532.
    PubMed     Text format     Abstract available


  69. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
    Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in MDR-TB Patients.
    Antimicrob Agents Chemother. 2016 Sep 6. pii: AAC.00632.
    PubMed     Text format     Abstract available


    August 2016
  70. NARAN K, Moosa A, Barry CE 3rd, Boshoff HI, et al
    Bioluminescent reporters for rapid mechanism of action assessment in tuberculosis drug discovery.
    Antimicrob Agents Chemother. 2016 Aug 29. pii: AAC.01178.
    PubMed     Text format     Abstract available


  71. ZHANG D, Gomez JE, Chien JY, Haseley N, et al
    Genomic analysis of the evolution of fluoroquinolone resistance in Mycobacterium tuberculosis prior to tuberculosis diagnosis.
    Antimicrob Agents Chemother. 2016 Aug 29. pii: AAC.00664.
    PubMed     Text format     Abstract available


  72. FURIN JJ, Du Bois J, van Brakel E, Chheng P, et al
    Early Bactericidal Activity of AZD5847 in Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2016 Aug 22. pii: AAC.01163.
    PubMed     Text format     Abstract available


  73. CHUANG YM, Dutta NK, Hung CF, Wu TC, et al
    The stringent response factors PPX1 and PPK2 play an important role in Mycobacterium tuberculosis metabolism, biofilm formation, and sensitivity to isoniazid in vivo.
    Antimicrob Agents Chemother. 2016 Aug 15. pii: AAC.01139.
    PubMed     Text format     Abstract available


  74. FOO CS, Lechartier B, Kolly GS, Boy-Rottger S, et al
    Characterization of DprE1-mediated benzothiazinone resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Aug 15. pii: AAC.01523.
    PubMed     Text format     Abstract available


  75. NIKONENKO BV, Kornienko A, Majorov K, Ivanov P, et al
    In vitro activity of 3-triazenoindoles against Mycobacterium tuberculosis and Mycobacterium avium.
    Antimicrob Agents Chemother. 2016 Aug 8. pii: AAC.00998.
    PubMed     Text format     Abstract available


  76. PALENCIA A, Li X, Bu W, Choi W, et al
    Discovery of novel oral protein synthesis inhibitors of Mycobacterium tuberculosis that target leucyl-tRNA synthetase.
    Antimicrob Agents Chemother. 2016 Aug 8. pii: AAC.01339.
    PubMed     Text format     Abstract available


  77. CORDES H, Thiel C, Aschmann HE, Baier V, et al
    A PBPK model of isoniazid and its application in individualizing tuberculosis chemotherapy.
    Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.00508.
    PubMed     Text format     Abstract available


  78. ROCKWOOD NN, Meintjes G, Chirehwa M, Wiesner L, et al
    HIV-1 co-infection does not reduce exposure to rifampicin, isoniazid, and pyrazinamide in South African tuberculosis outpatients.
    Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.00480.
    PubMed     Text format     Abstract available


  79. PROSSER GA, Rodenburg A, Khoury H, de Chiara C, et al
    Glutamate racemase is the primary target of beta-chloro-D-alanine in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.01249.
    PubMed     Text format     Abstract available


    July 2016
  80. MODONGO C, Pasipanodya JG, Magazi BT, Srivastava S, et al
    Artificial intelligence and amikacin exposures predictive of outcome in multidrug-resistant tuberculosis patients.
    Antimicrob Agents Chemother. 2016 Jul 25. pii: AAC.00962.
    PubMed     Text format     Abstract available


  81. GARCIA-GARCIA V, Oldfield E, Benaim G
    Inhibition of Leishmania mexicana Growth by the Tuberculosis Drug SQ109.
    Antimicrob Agents Chemother. 2016 Jul 25. pii: AAC.00945.
    PubMed     Text format     Abstract available


  82. SRIVASTAVA S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, et al
    Amikacin optimal exposures targets in the hollow fiber system model of tuberculosis.
    Antimicrob Agents Chemother. 2016 Jul 25. pii: AAC.00961.
    PubMed     Text format     Abstract available


  83. SHAH S, Dalecki AG, Malalasekera AP, Crawford CL, et al
    8-Hydroxyquinolines are boosting-agents of copper related toxicity in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Jul 18. pii: AAC.00325.
    PubMed     Text format     Abstract available


    June 2016
  84. YU X, Wang G, Chen S, Wei G, et al
    Mycobacterium tuberculosis wild-type and non-wild-type MIC distributions for the novel fluoroquinolone antofloxacin compared with ofloxacin, levofloxacin, and moxifloxacin.
    Antimicrob Agents Chemother. 2016 Jun 20. pii: AAC.00393.
    PubMed     Text format     Abstract available


  85. DISRATTHAKIT A, Prammananan T, Tribuddharat C, Thaipisuttikul I, et al
    Gyrase Mutations in Pre-extensively and Extensively Drug-resistant Tuberculosis in Thai Clinical Isolates: Insights into the Role of gyrB Mutations in Quinolone Resistance.
    Antimicrob Agents Chemother. 2016 Jun 13. pii: AAC.00539.
    PubMed     Text format     Abstract available


  86. LI W, Obregon-Henao A, Wallach JB, North EJ, et al
    Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3.
    Antimicrob Agents Chemother. 2016 Jun 13. pii: AAC.00826.
    PubMed     Text format     Abstract available


  87. LI D, Hu Y, Werngren J, Mansjo M, et al
    Emergence and genetic characteristics of pyrazinamide resistant tuberculosis in China, a multi-center study.
    Antimicrob Agents Chemother. 2016 Jun 13. pii: AAC.02687.
    PubMed     Text format     Abstract available


  88. DEN HERTOG AL, Menting S, Pfeltz R, Warns M, et al
    PZA is active against Mycobacterium tuberculosis cultures at neutral pH with reduced temperature.
    Antimicrob Agents Chemother. 2016 Jun 6. pii: AAC.00654.
    PubMed     Text format     Abstract available


    May 2016
  89. ZHENG X, Zheng R, Hu Y, Werngren J, et al
    Determination of Minimum Inhibitory Concentration (MIC) Breakpoints for second-line drugs associated with clinical outcomes in multidrug-resistant tuberculosis treatment in China.
    Antimicrob Agents Chemother. 2016 May 31. pii: AAC.03008.
    PubMed     Text format     Abstract available


  90. HU Y, Pertinez H, Ortega-Muro F, Alameda-Martin L, et al
    Investigation of elimination rate, persistent subpopulation removal and relapse rates of Mycobacterium tuberculosis by combinations of first-line drugs in a modified Cornell mouse model.
    Antimicrob Agents Chemother. 2016 May 23. pii: AAC.02548.
    PubMed     Text format     Abstract available


  91. CHIEN JY, Chien ST, Chiu WY, Yu CJ, et al
    Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-resistant Multidrug-resistant Tuberculosis.
    Antimicrob Agents Chemother. 2016 May 23. pii: AAC.00425.
    PubMed     Text format     Abstract available


  92. ALMEIDA D, Ioerger T, Tyagi S, Li SY, et al
    Mutations in pepQ Confer Low-level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 May 16. pii: AAC.00753.
    PubMed     Text format     Abstract available


  93. NIGHTINGALE S, Chau TT, Fisher M, Nelson M, et al
    Efavirenz and metabolites in CSF; relationship with CYP2B6 c.516G>T genotype and perturbed blood-brain barrier due to tuberculous meningitis.
    Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00280.
    PubMed     Text format     Abstract available


  94. LINGARAJU S, Rigouts L, Gupta A, Lee J, et al
    Geographic differences in the contribution of ubiA mutations to high-level Ethambutol Resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 May 2. pii: AAC.03002.
    PubMed     Text format     Abstract available


  95. LANOIX JP, Tasneen R, O'Brien P, Sarathy J, et al
    High systemic exposure of pyrazinoic acid has limited anti-tuberculosis activity in murine and rabbit models of tuberculosis.
    Antimicrob Agents Chemother. 2016 May 2. pii: AAC.03085.
    PubMed     Text format     Abstract available


    April 2016
  96. LEE JY, Lee HJ, Kim YK, Yu S, et al
    Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients.
    Antimicrob Agents Chemother. 2016 Apr 18. pii: AAC.01749.
    PubMed     Text format     Abstract available


  97. GEORGHIOU SB, Seifert M, Catanzaro D, Garfein RS, et al
    Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.
    Antimicrob Agents Chemother. 2016 Apr 18. pii: AAC.00222.
    PubMed     Text format     Abstract available


  98. ALSAAD N, Dijkstra JA, Akkerman OW, de Lange WC, et al
    A pharmacokinetic evaluation of sulfamethoxazole 800 mg once daily in the treatment of tuberculosis.
    Antimicrob Agents Chemother. 2016 Apr 11. pii: AAC.02175.
    PubMed     Text format     Abstract available


  99. EARLY JV, Casey A, Martinez-Grau MA, Valcarcel IC, et al
    Oxadiazoles have butyrate-specific conditional activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Apr 4. pii: AAC.02896.
    PubMed     Text format     Abstract available


    March 2016
  100. MORADIGARAVAND D, Grandjean L, Martinez E, Li H, et al
    DfrA-thyA double deletion in para-aminosalicylic acid resistant Mycobacterium tuberculosis Beijing strains.
    Antimicrob Agents Chemother. 2016 Mar 28. pii: AAC.00253.
    PubMed     Text format     Abstract available


  101. PARVEZ MM, Jung JA, Shin HJ, Kim DH, et al
    Characterization of 22 anti-tuberculosis drugs for the inhibitory interaction potential on organic anionic transporter polypeptides (OATPs) mediated uptake.
    Antimicrob Agents Chemother. 2016 Mar 14. pii: AAC.02765.
    PubMed     Text format     Abstract available


  102. STINSON K, Kurepina N, Venter A, Fujiwara M, et al
    Minimum Inhibitory Concentration of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
    Antimicrob Agents Chemother. 2016 Mar 14. pii: AAC.03014.
    PubMed     Text format     Abstract available


  103. MAKAFE GG, Cao Y, Tan Y, Julius M, et al
    Oxazolidinone Resistance in Mycobacterium tuberculosis: What is the Role of Cys154Arg Mutation in the Ribosomal Protein L3?
    Antimicrob Agents Chemother. 2016 Mar 7. pii: AAC.00152.
    PubMed     Text format     Abstract available


    February 2016
  104. SRIVASTAVA S, van Rijn SP, Wessels AM, Alffenaar JC, et al
    Susceptibility testing of antibiotics that degrade faster than the doubling-time of slow growing Mycobacteria; Ertapenem sterilizing effect versus Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Feb 29. pii: AAC.02924.
    PubMed     Text format     Abstract available


  105. SWANSON R, Ammerman N, Ngcobo B, Adamson J, et al
    Clofazimine contributes sustained antimicrobial activity after treatment cessation in the mouse model of tuberculosis chemotherapy.
    Antimicrob Agents Chemother. 2016 Feb 29. pii: AAC.00177.
    PubMed     Text format     Abstract available


  106. HENDON-DUNN CL, Doris KS, Thomas SR, Allnutt JC, et al
    A flow cytometry method for rapidly assessing M. tuberculosis responses to antibiotics with different modes of action.
    Antimicrob Agents Chemother. 2016 Feb 22. pii: AAC.02712.
    PubMed     Text format     Abstract available


  107. LI QJ, Jiao WW, Yin QQ, Xu F, et al
    Compensatory Mutations of Rifampicin Resistance Are Associated with Transmission of Multidrug Resistant Mycobacterium tuberculosis Beijing genotype strains in China.
    Antimicrob Agents Chemother. 2016 Feb 22. pii: AAC.02358.
    PubMed     Text format     Abstract available


  108. PEARSON CS, Kloos Z, Murray B, Tabe E, et al
    Combined Bioinformatic and Rational Design Approach to Develop Antimicrobial Peptides against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Feb 22. pii: AAC.00940.
    PubMed     Text format     Abstract available


  109. SCHERR N, Pluschke G, Panda M
    A comparative study of activities of a diverse set of anti-mycobacterial agents against Mycobacterium tuberculosis and Mycobacterium ulcerans.
    Antimicrob Agents Chemother. 2016 Feb 16. pii: AAC.02658.
    PubMed     Text format     Abstract available


  110. TURAPOV O, O'Connor BD, Sarybaeva AA, Williams C, et al
    Phenotypically adapted Mycobacterium tuberculosis populations from sputum are tolerant to first line drugs.
    Antimicrob Agents Chemother. 2016 Feb 16. pii: AAC.01380.
    PubMed     Text format     Abstract available


  111. DAS MK, Arya R, Debnath S, Debnath R, et al
    Global urine metabolomics of first line tuberculosis drug treated patients and identification of a novel metabolite of ethambutol.
    Antimicrob Agents Chemother. 2016 Feb 1. pii: AAC.02586.
    PubMed     Text format     Abstract available


    January 2016
  112. ZHANG S, Chen J, Cui P, Shi W, et al
    Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.
    Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02941.
    PubMed     Text format     Abstract available


  113. BEKKER A, Schaaf HS, Draper HR, van der Laan L, et al
    The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants dosed at revised WHO-recommended treatment guidelines.
    Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02600.
    PubMed     Text format     Abstract available


  114. CHIEN JY, Chiu WY, Chien ST, Chiang CJ, et al
    Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-resistant Mycobacterium tuberculosis Isolates.
    Antimicrob Agents Chemother. 2016 Jan 19. pii: AAC.01049.
    PubMed     Text format     Abstract available


  115. NUERMBERGER E, Sizemore C, Romero K, Hanna D, et al
    Towards an evidence-based non-clinical roadmap for evaluating the efficacy of new TB drug regimens: Proceedings of a Critical Path to TB Drug Regimens (CPTR)-National Institute of Allergy and Infectious Disease (NIAID) in vivo Pharmacology Workshop fo
    Antimicrob Agents Chemother. 2016 Jan 11. pii: AAC.02041.
    PubMed     Text format     Abstract available


    December 2015
  116. LANOIX JP, Betoudji F, Nuermberger E
    Sterilizing activity of pyrazinamide in combination with first-line drugs in a C3HeB/FeJ mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2015 Dec 7. pii: AAC.02637.
    PubMed     Text format     Abstract available


  117. DENTI P, Martinson N, Cohn S, Mashabela F, et al
    Population pharmacokinetics of rifampicin in pregnant women with tuberculosis and HIV co-infection in Soweto, South Africa.
    Antimicrob Agents Chemother. 2015 Dec 7. pii: AAC.02051.
    PubMed     Text format     Abstract available


    November 2015
  118. LANOIX JP, Ioerger T, Ormond A, Kaya F, et al
    Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum.
    Antimicrob Agents Chemother. 2015 Nov 16. pii: AAC.01370.
    PubMed     Text format     Abstract available


  119. CHIREHWA MT, Rustomjee R, Mthiyane T, Onyebujoh P, et al
    Model-based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of hepatic extraction.
    Antimicrob Agents Chemother. 2015 Nov 9. pii: AAC.01830.
    PubMed     Text format     Abstract available


  120. LEE H, Jeong BH, Park HY, Jeon K, et al
    Treatment Outcomes of Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2015 Nov 2. pii: AAC.01377.
    PubMed     Text format     Abstract available


  121. ZHANG D, Wang Y, Lu J, Pang Y, et al
    In vitro activity of beta-lactams in combination with beta-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis isolates.
    Antimicrob Agents Chemother. 2015 Nov 2. pii: AAC.01035.
    PubMed     Text format     Abstract available


    October 2015
  122. SORRENTINO F, Gonzalez Del Rio R, Zheng X, Presa JM, et al
    Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages.
    Antimicrob Agents Chemother. 2015 Oct 26. pii: AAC.01920.
    PubMed     Text format     Abstract available


  123. TASNEEN R, Betoudji F, Tyagi S, Li SY, et al
    Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2015 Oct 26. pii: AAC.01691.
    PubMed     Text format     Abstract available


  124. HENNIG S, Naiker S, Reddy T, Egan D, et al
    The effect of SLCO1B1 polymorphisms on the pharmacokinetics of rifabutin in African HIV-infected patients with tuberculosis.
    Antimicrob Agents Chemother. 2015 Oct 19. pii: AAC.01195.
    PubMed     Text format     Abstract available


  125. PARK JS, Lee JY, Lee YJ, Kim SJ, et al
    Serum levels of anti-tuberculosis drugs and their effect on tuberculosis treatment outcome.
    Antimicrob Agents Chemother. 2015 Oct 12. pii: AAC.00693.
    PubMed     Text format     Abstract available


  126. MEDELLIN-GARIBAY SE, Cortez-Espinosa N, Milan-Segovia RC, Magana-Aquino M, et al
    CLINICAL PHARMACOKINETICS OF RIFAMPICIN IN PATIENTS WITH TUBERCULOSIS AND TYPE 2 DIABETES MELLITUS: ASSOCIATION WITH BIOCHEMICAL AND IMMUNOLOGICAL PARAMETERS.
    Antimicrob Agents Chemother. 2015 Oct 5. pii: AAC.01067.
    PubMed     Text format     Abstract available


  127. PIRES D, Valente E, Simoes MF, Carmo N, et al
    Esters of pyrazinoic acid are active against pyrazinamide-resistant strains of Mycobacterium tuberculosis and other naturally resistant mycobacteria in vitro and ex vivo within macrophages.
    Antimicrob Agents Chemother. 2015 Oct 5. pii: AAC.00936.
    PubMed     Text format     Abstract available


  128. MAIGA MC, Ahmadou Ahidjo B, Maiga M, Bishai WR, et al
    Roflumilast, a type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2015 Oct 5. pii: AAC.02145.
    PubMed     Text format     Abstract available


    September 2015
  129. RUEDA J, Realpe T, Mejia GI, Zapata E, et al
    Genotypic analysis of genes associated with independent and cross-resistance to Isoniazid and Ethionamide in M. tuberculosis clinical isolates.
    Antimicrob Agents Chemother. 2015 Sep 14. pii: AAC.01028.
    PubMed     Text format     Abstract available


  130. PETERSON ND, Rosen BC, Dillon NA, Baughn AD, et al
    Uncoupling environmental pH and intrabacterial acidification from pyrazinamide susceptibility in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2015 Sep 14. pii: AAC.00967.
    PubMed     Text format     Abstract available


    August 2015
  131. HEYSELL SK, Pholwat S, Mpagama SG, Pazia SJ, et al
    Sensititre MYCOTB plate compared to Bactec MGIT 960 for first and second-line anti-tuberculosis drug susceptibility testing in Tanzania: a call to operationalize minimum inhibitory concentrations.
    Antimicrob Agents Chemother. 2015 Aug 24. pii: AAC.01117.
    PubMed     Text format     Abstract available


  132. WINGLEE K, Lun S, Pieroni M, Kozikowski A, et al
    Mutation of Rv2887, a marR-like gene, confers Mycobacterium tuberculosis resistance to an imidazopyridine-based agent.
    Antimicrob Agents Chemother. 2015 Aug 24. pii: AAC.01341.
    PubMed     Text format     Abstract available


  133. KAUSHIK A, Makkar N, Pandey P, Parrish N, et al
    Carbapenems and Rifampicin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2015 Aug 10. pii: AAC.01158.
    PubMed     Text format     Abstract available


  134. GOLD B, Roberts J, Ling Y, Lopez Quezada L, et al
    Rapid, semi-quantitative assay to discriminate among compounds with activity against replicating or non-replicating Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2015 Aug 3. pii: AAC.00803.
    PubMed     Text format     Abstract available


    July 2015
  135. VAN OOSTERHOUT JJ, Dzinjalamala FK, Dimba A, Waterhouse D, et al
    Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi.
    Antimicrob Agents Chemother. 2015 Jul 27. pii: AAC.01193.
    PubMed     Text format     Abstract available


  136. MODONGO C, Pasipanodya JG, Zetola NM, Williams SM, et al
    Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients.
    Antimicrob Agents Chemother. 2015 Jul 27. pii: AAC.01050.
    PubMed     Text format     Abstract available


  137. VERDUGO D, Fallows D, Ahuja S, Schluger N, et al
    Epidemiologic correlates of pyrazinamide resistant Mycobacterium tuberculosis in New York City.
    Antimicrob Agents Chemother. 2015 Jul 20. pii: AAC.00764.
    PubMed     Text format     Abstract available


  138. GARCIA-PRATS AJ, Draper HR, Thee S, Dooley KE, et al
    The pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2015 Jul 20. pii: AAC.01404.
    PubMed     Text format     Abstract available


  139. OGWANG S, Good C, Okware B, Nsereko M, et al
    Sulfamethoxazole Susceptibility of Mycobacterium tuberculosis Isolates from HIV-infected Ugandan Adults with Tuberculosis Taking Trimethoprim-Sulfamethoxazole Prophylaxis.
    Antimicrob Agents Chemother. 2015 Jul 13. pii: AAC.01101.
    PubMed     Text format     Abstract available


  140. DEMARCO VP, Ordonez AA, Klunk M, Prideaux B, et al
    Determination of 11C-Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice Using Dynamic Positron Emission Tomography Bioimaging.
    Antimicrob Agents Chemother. 2015 Jul 13. pii: AAC.01146.
    PubMed     Text format     Abstract available


  141. SOROKA D, Li de la Sierra-Gallay I, Dubee V, Triboulet S, et al
    Hydrolysis of clavulanate by Mycobacterium tuberculosis beta-lactamase BlaC harboring a canonic SDN motif.
    Antimicrob Agents Chemother. 2015 Jul 6. pii: AAC.00598.
    PubMed     Text format     Abstract available


  142. SINGH R, Ramachandran V, Shandil R, Sharma S, et al
    In silico based high through put screen for discovery of novel combinations for the treatment for tuberculosis.
    Antimicrob Agents Chemother. 2015 Jul 6. pii: AAC.05148.
    PubMed     Text format     Abstract available


    June 2015
  143. CUEVAS-CORDOBA B, Juarez Eusebio DM, Almaraz-Velazco R, Muniz-Salazar R, et al
    Mutation at embB 306, a potential marker for the identification of multidrug resistance associated with ethambutol in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2015 Jun 29. pii: AAC.00117.
    PubMed     Text format     Abstract available


  144. WILLBY M, Sikes RD, Malik S, Metchock B, et al
    Correlation between GyrA mutations and ofloxacin, levofloxacin and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2015 Jun 22. pii: AAC.00662.
    PubMed     Text format     Abstract available


  145. HAVER HL, Chua A, Ghode P, Lakshminarayana SB, et al
    Mutations in the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro selected PA-824 mutants of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2015 Jun 22. pii: AAC.00308.
    PubMed     Text format     Abstract available


  146. RAMIREZ-BUSBY SM, Valafar F
    A Systematic Review of Mutations in Pyrazinamidase Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis Clinical Isolates.
    Antimicrob Agents Chemother. 2015 Jun 15. pii: AAC.00204.
    PubMed     Text format     Abstract available


  147. STURKENBOOM MG, Mulder LW, de Jager A, van Altena R, et al
    Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2015 Jun 8. pii: AAC.00756.
    PubMed     Text format     Abstract available


  148. DALECKI AG, Haeili M, Shah S, Speer A, et al
    Disulfiram and copper ions kill Mycobacterium tuberculosis in a synergistic manner.
    Antimicrob Agents Chemother. 2015 Jun 1. pii: AAC.00692.
    PubMed     Text format     Abstract available


  149. BROSSIER F, Sougakoff W, Bernard C, Petrou M, et al
    Molecular analysis of the embCAB locus and embR gene involved in resistance to ethambutol in clinical isolates of Mycobacterium tuberculosis in France.
    Antimicrob Agents Chemother. 2015 Jun 1. pii: AAC.00150.
    PubMed     Text format     Abstract available


  150. MINATO Y, Thiede JM, Kordus SL, McKlveen EJ, et al
    Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.
    Antimicrob Agents Chemother. 2015 Jun 1. pii: AAC.00647.
    PubMed     Text format     Abstract available


    May 2015
  151. LECHARTIER B, Cole ST
    Insight into the mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2015 May 18. pii: AAC.00395.
    PubMed     Text format     Abstract available


  152. PARK SI, Oh J, Jang K, Yoon J, et al
    Pharmacokinetics of Second-line Anti-Tuberculosis Drugs after Multiple Administrations in Healthy Volunteers.
    Antimicrob Agents Chemother. 2015 May 18. pii: AAC.00354.
    PubMed     Text format     Abstract available


  153. MAKAROV V, Neres J, Hartkoorn RC, Ryabova OB, et al
    8-Pyrrole-benzothiazinones non-covalent inhibitors of DprE1 from Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2015 May 18. pii: AAC.00778.
    PubMed     Text format     Abstract available


  154. JOHNSON BK, Colvin CJ, Needle DB, Mba Medie F, et al
    The carbonic anhydrase inhibitor ethoxzolamide inhibits the Mycobacterium tuberculosis PhoPR regulon, Esx-1 secretion and attenuates virulence.
    Antimicrob Agents Chemother. 2015 May 18. pii: AAC.00719.
    PubMed     Text format     Abstract available


  155. SY SK, de Kock L, Diacon AH, Werely CJ, et al
    N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in drug-resistant pulmonary tuberculosis patients.
    Antimicrob Agents Chemother. 2015 May 11. pii: AAC.04049.
    PubMed     Text format     Abstract available


    February 2015
  156. GUMBO T, Pasipanodya JG, Wash P, Burger A, et al
    Reply to "breakpoints and drug exposure are inevitably closely linked".
    Antimicrob Agents Chemother. 2015;59:1385.
    PubMed     Text format    


  157. ALFFENAAR JW, Akkerman OW, Bolhuis MS, Boeree MJ, et al
    Breakpoints and drug exposure are inevitably closely linked.
    Antimicrob Agents Chemother. 2015;59:1384.
    PubMed     Text format    


    December 2014
  158. RAMACHANDRAN G, Kumar AK, Bhavani PK, Kannan T, et al
    Pharmacokinetics of first-line anti-TB drugs in HIV-infected children with TB treated with intermittent regimens in India.
    Antimicrob Agents Chemother. 2014 Dec 8. pii: AAC.04338.
    PubMed     Text format     Abstract available


    September 2014
  159. REQUENA-MENDEZ A, Davies G, Waterhouse D, Ardrey A, et al
    Effect of dosage, co-morbidities and food on pharmacokinetics of isoniazid in Peruvian TB patients.
    Antimicrob Agents Chemother. 2014 Sep 15. pii: AAC.03258.
    PubMed     Text format     Abstract available


    August 2014
  160. SVENSSON EM, Dooley KE, Karlsson MO
    Impact of lopinavir/ritonavir or nevirapine on bedaquiline exposures: potential implications for patients with TB/HIV co-infection.
    Antimicrob Agents Chemother. 2014 Aug 11. pii: AAC.03246.
    PubMed     Text format     Abstract available


  161. SUN F, Ruan Q, Wang J, Chen S, et al
    Linezolid manifests a rapid and dramatic therapeutic effect for patients with life threatening tuberculous meningitis.
    Antimicrob Agents Chemother. 2014 Aug 4. pii: AAC.02784.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: